Executive Leadership

Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive

Song Li, Ph.D.

Song Li, Ph.D.

Founder and Chief Executive Officer
Song Li, Ph.D.

Song Li, Ph.D.

Founder and Chief Executive Officer

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently the “Realizing the American Dream” award from the Pennsylvania Welcoming Society and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

Read Full Bio
Zeke Li, MD

Zeke Li, MD

Senior Vice President, China Operations
Zeke Li, MD

Zeke Li, MD

Senior Vice President, China Operations

Dr. Zeke Li is responsible for global project management functions and the company’s corporate strategy. As one of the founders and board members of Frontage, Dr. Li has more than 20 years of related experience that began with post-doctoral training at the National Institutes of Health. Prior to Frontage, he served as Group Leader, Preclinical and Pharmacology for Scios Inc., a Johnson and Johnson company. In recent years, Dr. Li has interacted extensively with Chinese biopharmaceutical companies on novel and generic development projects. With in-depth experience in research and development of small molecules, peptides and protein drugs, he has authored and co-authored more than 40 scientific papers and patents.

Dr. Li received his medical degree and a master’s degree in pathology from Norman Bethune University of Medical Sciences in China. He earned a doctor of philosophy degree in pathology from McGill University.

Read Full Bio
Philip Doren, Ph.D.

Philip Doren, Ph.D.

President of Clinical Services
Philip Doren, Ph.D.

Philip Doren, Ph.D.

President of Clinical Services

As President of Clinical Services, Dr. Doren directs strategy and growth of the company, evaluates and secures early clinical and biometric opportunities, and develops relationships with strategic partners to expand our services in key areas of support.

Dr. Doren has over 25 years of experience in developing and managing external partnerships in the CRO industry.  Prior to Frontage Clinical Services, he was most recently with Everest Clinical Research where he served as General Manager and Vice President of Clinical Operations and was responsible for development of the biometrics-focused business and established the Clinical Services business.  Prior to Everest, he served as Global Vice President of Biometrics at SynteractHCR (2012-2015); Vice President, Clinical Data, Analysis, and Reporting Organization at Covance (2008 – 2012); Vice President, Head of Biostatistics – North America, Quintiles (2003 – 2008).

Philip received his M.S. and Ph.D. in quantitative genetics from Texas A&M University.

Read Full Bio
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President and General Manager, CMC Services
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President and General Manager, CMC Services

Dr. Dongmei Wang is General Manager of Frontage’s CMC services group. With more than 20 years of pharmaceutical development experience, Dr. Wang’s CMC oversight spans organic synthesis, formulation development, GMP analytical testing, and GMP manufacturing of clinical trial materials. Prior to joining Frontage, Dr. Wang served as the Director of Analytical at NovaDel Pharma Inc., where she led teams in providing support for NDA product development, clinical supplies manufacturing, CMC sections of regulatory filings, and technology transfer to commercial manufacturing sites.

Prior to NovaDel, Dr. Wang headed pharmaceutical analysis and control functions at Therics Inc. in product development for 510(k) and IND filings. Earlier in her career, Dr. Wang was a lecturer at the Chinese Academy of Science.

Dr. Wang earned a doctor of philosophy degree in chemistry with honors from Iowa State University. She received a master’s of science degree in chemical engineering and a bachelor’s degree in chemistry from Peking University in China.

Read Full Bio
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Bioanalytical and Biologics Services
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Bioanalytical and Biologics Services

As Senior Vice President, Bioanalytical and Biologics Services, Dr. John Lin leads operations for the company’s global bioanalytical labs. Before joining Frontage, he served as a business leader in AstraZeneca’s global drug metabolism and pharmacokinetics (DMPK) division. Prior to AstraZeneca, Dr. Lin was Laboratory Director for Avantix Laboratories.

With more than 20 years of experience, Dr. Lin’s current research focus is in the area of bioanalytical method development and validation, dry blood spot (DBS) sampling with LC-MS/MS analysis, and biomarker quantification using LC-MS/MS. He has contributed to more than 20 research publications covering the development and validation of LC-MS/MS methods for the determination of small and large molecules in biological matrices, four book chapters and one technical patent. He is the invited reviewer for several international journals including the Journal of Pharmaceutical Biomedical Analysis (JPBA) and Journal of Chromatography B (JCB).

Dr. Lin earned a doctor of philosophy degree in analytical chemistry from Dalhousie University in Canada. He received a master’s degree in analytical chemistry from Yunnan University and a bachelor of science degree in chemistry from Fuzhou Branch School of Jiangxi Normal College. Dr. Lin completed post-doctoral research in pharmacokinetics and metabolism at the College of Pharmacy and the Comprehensive Cancer Center of the Ohio State University.

Read Full Bio
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President of Drug Metabolism and Pharmacokinetics
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President of Drug Metabolism and Pharmacokinetics

Dr. Abdul Mutlib is Vice President of Drug Metabolism and Pharmacokinetics, and leads operations for this service group.  Prior to joining Frontage in 2010, he held director-level roles within drug metabolism teams at Wyeth and Pfizer. Earlier in his career, he held scientific positions on the drug metabolism teams at Hoechst-Roussel and DuPont-Merck.  With more than 20 years of experience in drug metabolism and analytical chemistry, Dr. Mutlib’s research includes application of various analytical techniques and stable isotope labeled compounds in elucidating structures of metabolites and metabolic pathways; mass spectrometry; qualitative and quantitative NMR; metabolism-mediated toxicities; reactive metabolites; phase II metabolism; drug-drug interactions; and toxicogenomics. He has published more than sixty papers in peer-reviewed journals.

Dr. Mutlib earned a bachelor’s degree in pharmacy and a doctor of philosophy degree in pharmaceutical chemistry from the University of Sydney in Australia. He completed post-doctoral fellowships at Universities of Washington and British Columbia.

Read Full Bio
Harry Zhao, Ph.D.

Harry Zhao, Ph.D.

Senior Vice President, Bioanalytical Services
Harry Zhao, Ph.D.

Harry Zhao, Ph.D.

Senior Vice President, Bioanalytical Services

Dr. Zhao is Senior Vice President, Bioanalytical Services. A Frontage employee since its founding, Dr. Zhao established the company’s bioanalytical laboratory functions and currently manages the information technology infrastructure, facilities and service of bioanalytical laboratories. He is responsible for assuring facilities and instrumentation are maintained and operated under the highest standards and meet international compliance standards.

Prior to Frontage, Dr. Zhao was as senior scientist working on the development of mass spectrometers for Spectru Medix Corporation. Earlier, he worked for Ames Laboratory in the research department. Dr. Zhao began his career as a chemistry instructor at Zhengzhou University in China.

Dr. Zhao received a doctor of philosophy degree in chemistry from Iowa State University. He earned a masters and bachelor’s degree of science in physical chemistry from Zhengzhou University.

Read Full Bio
Wendy Webber Nelson, Ph.D.

Wendy Webber Nelson, Ph.D.

Vice President, Business Development, Marketing and Strategic Alliance
Wendy Webber Nelson, Ph.D.

Wendy Webber Nelson, Ph.D.

Vice President, Business Development, Marketing and Strategic Alliance

Wendy Webber Nelson, Ph.D., is the Vice President of Business Development, Marketing and Strategic Alliance. Wendy joined Frontage with nearly 20 years of industry experience, most recently serving in business development roles at various global CROs. Prior to working in business development, Wendy was responsible for Project Management and Operations with Alantos Pharmaceuticals and participated in the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. She began her career in R&D at Alkermes, Inc. where she worked in formulations.

Wendy is also Founder and President of the Boston Biotech Forum, which she initiated to foster networking and address pertinent industry topics with technical experts from over 90 local biotechnology and pharmaceutical companies.

Wendy is an inventor on multiple patents and patent applications, and is the senior author of a number of scientific publications and book chapters. She received her ScB and MS in Engineering and PhD in Medical Sciences from Brown University.

Read Full Bio